Babies, Blemishes and FDA: A History of Accutane Regulation in the United States

DSpace/Manakin Repository

dc.contributor.advisor	Hutt, Peter Barton	en_US
dc.contributor.author	Green, Julia	en_US
dc.date.accessioned	2012-07-06T20:09:14Z
dc.date.issued	2002	en_US
dc.identifier.citation	Babies, Blemishes and FDA: A History of Accutane Regulation in the United States (2002 Third Year Paper)	en
dc.identifier.uri	http://nrs.harvard.edu/urn-3:HUL.InstRepos:8963867
dc.description.abstract	This paper takes a journalistic approach, tracing the chronology of Accutane in the U.S. in order to fill in the gaps of the story that has inspired so much controversy. Accutane has repeatedly pushed the frontier of FDA regulation, as the agency struggled to adapt its tools to meet the challenge of an extremely effective and extremely dangerous medication. By emphasizing the evolving American response to the high level of risk associated with Accutane, I hope to provide the material needed to evaluate the strengths and weaknesses of our current regulatory framework.	en
dc.language.iso	en_US	en
dash.license	LAA	en_US
dc.subject	Food and Drug Law	en
dc.subject	Accutane	en
dc.subject	FDA	en
dc.subject	dangers	en
dc.subject	birth	en
dc.subject	defects	en
dc.title	Babies, Blemishes and FDA: A History of Accutane Regulation in the United States	en
dc.type	Paper (for course/seminar/workshop)	en_US
dc.date.available	2012-07-06T20:09:14Z